ESPE Abstracts

Emerging in childhood and becoming increasingly prevalent to affect 40-50% of adults with cystic fibrosis (CF), CF-related diabetes (CFRD) is a common co-morbidity with the potential to negatively impact nutritional status, pulmonary function, and survival. Stymying interventions to preserve beta-cell function, the mechanisms underlying the progressive insulin secretion defects responsible for CFRD are poorly delineated. This meet-the-professor session will use case-based presentations to review current diagnostic guidelines and recent literature surrounding alternatives to the standard oral glucose tolerance test (OGTT), consider management of abnormal glucose tolerance (AGT) and CFRD in the setting of various nutritional regimens and co-morbidities, and to appraise the potential impact of modulator therapy upon patients with AGT.